23615_br FDA APPROVES EXTENDED DOSING OF ARANESP®
- 00:00:57
- Google Video
23615_br FDA APPROVES EXTENDED DOSING OF ARANESP®
More than two-thirds of cancer patients in the U.S. receiving chemotherapy develop anemia, a low red blood cell count. More than half of chemotherapy patients report that fatigue, a common symptom of anemia, affects their daily lives more than any other side effect of treatment, including nausea, pain and depression. Anemia treatments have been available for more than a decade, and treatment typically takes more than two hours per visit. Now, the FDA has approved every-three-week dosing of Aranesp, a medication that increases red blood cell counts, for the treatment of chemotherapy-induced anemia. This extended dosing can provide added convenience for patients and less injection-related burden for patients and health care professionals. Aranesp is the only anemia treatment approved for this less frequent dosing.
Google Video | April 20, 2006
